Evidence map›Paper›PMID 20533502›Full record

ArticleChemMedChem2010

HTS and rational drug design to generate a class of 5-HT(2C)-selective ligands for possible use in schizophrenia.

Alan P Kozikowski, Sung Jin Cho, Niels H Jensen, John A Allen, Andreas M Svennebring, Bryan L Roth

Abstract read
In one paragraph

Article in ChemMedChem, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. "Selective" serotonin 5-HTBiochemical pharmacology · 2022
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alan P KozikowskiDepartment of Medicinal Chemistry and Pharmacognosy, University of Illinois at Chicago, 60612-7230, USA. kozikowa@uic.edu
Sung Jin Cho
Niels H Jensen
John A Allen
Andreas M Svennebring
Bryan L Roth

Funding

Screening CoreU19MH082441 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CARON, MARC G., ROTH, BRYAN L. · 2007 to 2016
$15.2M
Postdoctoral Research in Neurodevelopmental DisordersT32HD040127 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENJAMIN D PHILPOT, Mark D Shen · 2001 to 2026
$8.5M
Targeting and Trafficking of 5-HT2A Serotonin ReceptorsR01MH061887 · NIMH · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L. · 2000 to 2014
$4.5M
Chemistry and Biology of 5-HT2C Receptor Ligands for Drug AbuseR01DA022317 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KOZIKOWSKI, ALAN P. · 2007 to 2010
$2.2M
NICHD NIH HHS T32 HD040127NICHD NIH HHS T32HD040127NIDA NIH HHS R01 DA022317NIMH NIH HHS N01 MH80032NIMH NIH HHS R01 MH061887NIMH NIH HHS R01 MH61887NIMH NIH HHS U19 MH082441NIMH NIH HHS U19 MH82441
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

LigandsSerotonin 5-HT2 Receptor AgonistsAnimalsCell LineClinical Trials as TopicCyclopropanesDrug DesignHigh-Throughput Screening AssaysHumansMethylaminesMicePhencyclidineReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2BReceptor, Serotonin, 5-HT2CSchizophreniaCyclopropanesLigandsMethylaminesPhencyclidineReceptor, Serotonin, 5-HT2AReceptor, Serotonin, 5-HT2BReceptor, Serotonin, 5-HT2CSerotonin 5-HT2 Receptor AgonistsSerotonin 5-HT2 Receptor Antagonists

Identifiers

PMID20533502
PMCPMC2951742

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.